The Neural Pleonastics- Neurofibroma

Bajaj A* 
Department of Consultant Histopathologist, A.B. Diagnostics, A-1, Ring Road, Rajouri Garden, New Delhi

*Corresponding author:
Anubha Bajaj,
Consultant Histopathologist, A.B. Diagnostics,
A-1, Ring Road,
Rajouri Garden, New Delhi 110027,
Tel: 009141446785,
E-mail: anubha.bajaj@gmail.com

Received: 10 Nov 2020
Accepted: 07 Dec 2020
Published: 12 Dec 2020

1. Preface
Neurofibroma is a fairly prevalent, benign, peripheral nerve sheath tumour composed of Schwann cells, fibroblasts, perineurial cells and mast cells disseminated within a variably myxoid or collagenous stroma. Neuronal element of transformed Schwann cells is admixed with non- neoplastic, fibrous element constituted of fibroblasts. Neurofibroma is generally engendered by chromosomal mutations within the neurofibromatosis 1 (NF1) gene.

2. Disease Characteristics
Majority (90%) of neurofibromas are sporadic and demonstrate a minimal possibility of malignant metamorphoses. An estimated 10% of lesions are associated with neurofibromatosis type 1 (NF1) or neurofibromatosis type 2 (NF2) disorder. Superficial neurofibroma is a common entity, in contrast to deep-seated neurofibroma [1,2]. Neurofibroma is subcategorized into
- Localized neurofibroma, frequently discerned
- Diffuse neurofibroma
- Plexiform neurofibroma.

As a frequently discerned neoplasm of peripheral nerve sheath, neurofibroma is devoid of gender, racial or ethnic preferences. Males and females are equally incriminated [1,2]. Localized neurofibroma is commonly discerned in adults between 20 years to 40 years although a variable age of disease onset is encountered. Diffuse and plexiform neurofibroma is frequently encountered in children although plexiform neurofibroma is exceptional beyond 5 years. Plexiform neurofibroma is a pathognomon-
Of obscure genesis, tumefaction arises from endoneurium and connective tissue enveloping peripheral nerve sheath. Tumour cells are immune reactive to CD34 whereas neural cells are immune reactive to S100 protein [3,4].

4. Clinical Elucidation
The neoplasm often appears as a soft, flesh coloured papule or miniature subcutaneous nodule. Subjects are commonly asymptomatic. However, irritation, mild pruritus, pain or paraesthesia can occur with cosmetic affliction. Clinical manifestations pertain to variant of neurofibroma [3].

Localized lesions arise as painless, flesh coloured, violaceous papule, nodule or subcutaneous mass and can be misinterpreted as a nevus or achrochordon. Typically, solitary lesions are below < 2 centimetres with a palpable “buttonhole sign” Localized neurofibroma depicts a predilection for trunk, head, neck, and extremities although no site of tumour emergence is exempt. Localized, superficial neurofibromas are evenly disseminated upon diverse body surfaces [3,4].

Sporadic or localized variant of neurofibroma, emerging in absence of mutated neurofibromatosis type I gene, is a painless, gradually progressive, solitary, flesh coloured, soft, flaccid, rubbery, firm papule or nodule of variable magnitude of up to 2 centimetres and a smooth extraneous surface. Cutaneous or subcutaneous neurofibromas arise as a component of neurofibromatosis type I (NF1) disorder [3,4].

Diffuse neurofibromatosis commonly appears within head and neck and manifest as ill-defined, indurated plaques with thickened, adjacent cutaneous surface. Enlarged lesions demonstrate mild numbness or tingling [4].

Plexiform neurofibroma is enlarged, circumscribes multiple and major nerve fascicles and commonly emerges upon the head and neck, trunk or extremities. Superficial lesions appear as flesh coloured or hyper-pigmented nodules. Deep-seated lesions emerging from spinal nerve roots are irregular, tortuous and manifest pain, numbness, paraesthesia, nodule formation and spinal nerve compression [3,4].

Inherited, diffuse or plexiform neurofibromas are associated with neurofibromatosis type I and demonstrate pertinent symptoms such as chronic pain, cosmetic disfigurement, social stigma and anxiety. Exceptionally, neurofibromatous neuropathy can emerge due to endoneurial fibrosis with altered concurrence between Schwann cells and collagen fibrils [3,4].

Neurofibromatosis type I is appropriately categorized with concurrence of two or more of following criterion
- ≥6 café au lait patches exceeding >0.5 centimetres in pre-pubertal individuals or >1.5 centimetres in post-pubertal individuals.
- ≥2 neurofibromas of a particular variant or a singular plexiform neurofibroma.
- axillary or inguinal freckling.
- ≥ 2 Lisch nodules.
- optic glioma.
- sphenoid dysplasia or cortical thinning of long bones in combination with or absence of pseudo-arthrosis.
- first degree relative with neurofibromatosis type I [3,4].

5. Histological Elucidation
Grossly, the neoplasm is elliptical, fusiform, encapsulated, well circumscribed, firm, grey/white, tan or flesh coloured nodule. Cut surface is pale, gelatinous, glistening, tan or grey/white. Localized neurofibroma appears as a fusiform nodule with foci of myxoid and cystic degeneration. Neurofibroma emerging from major nerve trunks is encapsulated with fusiform expansion of implicated nerve [4,5].

Neurofibroma of miniature nerves is well circumscribed and un-encapsulated. Deep-seated neoplasms can engender tortuous enlargement of peripheral nerves with consequent emergence of plexiform neurofibroma. Areas of degeneration, necrosis or haemorrhage are absent. Intersected, adherent nerve fibres appear as a component of the neoplasm [4,5].

Well circumscribed, localized neurofibroma is situated within the dermis or subcutaneous tissue. Dermal lesions are typically un-encapsulated and demonstrate a “grenz zone”, comprised of uninvolved dermis located between tumefaction and epidermis. Subcutaneous lesions are enveloped in a true capsule [4,5].

Enlarged, plexiform neurofibroma demonstrates multiple, tortuous, nerve fascicles designated as “bag of worms”.

On cytological evaluation, miniature subgroups and clusters of spindle-shaped cells are loosely articulated. Tumour cells display minimal cytoplasm with uniform, elliptical or elongated nuclei and absent nucleoli.

A neoplasm of minimal to moderate cellularity, haphazard dissemination of loosely configured, spindle-shaped cells with poorly defined cellular margins is delineated. The neoplasm is composed of interlacing fascicles of elongated cells incorporated with wavy, darkly-stained nuclei. Innumerable mast cells and stromal dissemination of collagen bundles of diverse magnitude with variable quantities of mucin is observed. Cellular component is intermixed within a myxoid to collagenous matrix. Encompassing coarse, collagen bundles are described as “shredded carrots” [4,5].

Cellular nuclei are miniature, hyperchromatic and wavy, recapitulating “diving dolphins” Occasional nuclear enlargement and smudgy chromatin is observed. Tumour cells may be incorporated with monomorphic “buckled” or “comma-shaped nuclei”. Foci of divergent cellular differentiation can exceptionally appear such as...
occurrence of melanin pigmented cells. Focal or diffuse nuclear atypia is observed. Multinucleated giant cells are exceptional. Mitotic figures are minimal to absent [4,5].

Comprehensive proliferation of peripheral nerve elements is encountered. Schwann cells depict wavy, serpentine nuclei with pointed ends and are disseminated within wire-like collagen fibrils. Stroma is mucoid-rich with enmeshed mast cells. Wagner-Meissner corpuscles, Pacinian corpuscles, fibroblasts and axons which can be emphasized with silver or acetylcholinesterase stain, neurofilament or neuron-specific enolase (NSE) are dispersed within the collagen [4,5].

Neurofibroma may infiltrate encompassing soft tissue. An epithelioid morphology can be exhibited although skeletal muscle differentiation is infrequent. Verocay bodies, nuclear palisading or hyalinised thickening of vessels walls is absent [4,5].

Diffuse neurofibroma is a poorly defined, expansible, cellular proliferation circumscribing cutaneous adnexal structures and extending into subcutaneous tissue with adipose tissue infiltration The neoplasm can entrap peripheral nerves or appear as an intraneural, diffuse neurofibroma. Characteristically, tumefaction displays pseudo-meissnerian corpuscles which are comprised of fibrillary or whorled Schwann cells [4,5].

Plexiform neurofibroma is constituted by multiple, entwined, hypertrophic nerve fascicles and classically demonstrates a serpentine pattern with multiple nodules. The variant denominates nodular, irregular expansion of nerve bundles and a prominent, enveloping myxoid matrix. Neoplasm is associated with neurofibromatosis type I. Tumefaction depicts perinuerial cells enmeshed within a predominantly myxoid or oedematous stroma with intermingled, thick, collagen fibres. Tumour cells can display cellular atypia, nuclear enlargement or hyperchromasia, contingent to degenerative alterations [4,5].

Focal cutaneous neurofibroma and intraneural neurofibroma are also defined as pertinent subcategories.

Frequently, localized subtype or infrequently, diffuse subtype demonstrate the following features
• enhanced cellularity in combination with or absence of atypia or elevated mitotic activity.
• pigmented lesions associated with melanin production.
• atypical or bizarre lesions with hyperchromatic, pleomorphic, atypical nuclei associated with degenerative alterations and a distinct, lamellar configuration.
• epithelioid variant demonstrating cohesive nests of epithelioid tumour cells.
• granular cell variant constituted of granular cells and eosinophils. Tumour recapitulates associated granular cell tumours.
• lipomatous variant with diffusely disseminated adipocytes which are intrinsic to the neoplasm.
• dendritic cell variant comprised of dendritic tumour cells with configuration of pseudo-rosettes.
• hybrid neurofibroma with intermingled schwannoma-like nodules discernible within a typical neurofibroma [4,5].

On ultrastructural examination, Schwann cells exhibit an axonal envelop with plasmalemmal invaginations, thus configuring mesaxons (Figure 1-8) [5].

Figure 1: Neurofibroma enunciating aggregates of spindle-shaped cells and mast cells intermingled within a collagen-rich stroma and lack of cellular atypia [9].

Figure 2: Neurofibroma demonstrating fascicles of spindle-shaped cells intermixed within a collagenous stroma and a superimposed epidermal layer [10].

Figure 3: Neurofibroma exhibiting bundles of spindle-shaped cells dispersed within a collagenous stroma and an absence of atypia [11].

Figure 4: Neurofibroma delineating well circumscribed, encapsulated nodular aggregates with adjacent fibrous tissue [12].

Figure 5: Neurofibroma depicting interlacing fascicles of spindle-shaped cells with dark, wavy nuclei and an encompassing collagenous stroma [13].

Figure 6: Neurofibroma enunciating bundles of spindle-shaped cells with wavy nuclei, absent mitosis and an enveloping collagen-rich stroma and a superimposed stratified squamous epithelium [14].
Neurofibroma is an intensely immune reactive to S100 protein, SOX10 and collagen type IV with fingerprint-like, immune reactive CD34. Immune reactivity to factor XIIIa can be beneficially adopted to differentiate neurofibroma from necrotized nevi. Tumefaction is focally immune reactive to calretinin and weakly immune reactive to epithelial membrane antigen (EMA) or podoplanin. Ki-67 proliferation index is minimal [1,2].

The neoplasm is immune reactive to myelin basic protein. An estimated 50% of tumour cells and Schwann cells are immune reactive to S100 protein. Spindle-shaped fibroblasts are immune reactive to CD34 with a distinct “fingerprint” pattern. Perineurial cells are occasionally immune reactive to epithelial membrane antigen (EMA). Intra-tumoural axons are immune reactive to neurofilament protein. Mucinous stroma is immune reactive to acid mucopolysaccharides. Staining with p16 can adequately demarcate atypical neurofibroma from low grade malignant peripheral nerve sheath tumour (1,2).

Excluding plexiform neurofibroma, the neoplasm is immune non-reactive to epithelial membrane antigen (EMA). Also, cytokeratin, smooth muscle actin (SMA) and desmin are immune non-reactive (1,2).

7. Differential Diagnosis

Neurofibroma mandates a segregation from malignant peripheral nerve sheath tumour which is an aggressive, neurogenic neoplasm emerging from peripheral nerve or pre-existing nerve sheath tumour such as neurofibroma. Approximately 50% neoplasms are concurrent with NF1 gene. Rapid tumour evolution in a preceding neurofibroma can indicate malignant metamorphism. Morphologically, admixed foci of neurofibroma may be discerned. Malignant zones demonstrate enhanced cellularity, mitosis and necrosis. Tumour cells of malignant peripheral nerve sheath tumour demonstrate miniature, wavy nuclei and minimal nuclear hyperchromasia. Abundant, “shredded carrot” category of collagen dissemination is observed. Fascicular tumour configuration and mitotic figures are exceptional. Tumour necrosis is absent. The neoplasm is intensely immune reactive to S100 protein, collagen type IV, CD34, SOX10, moderately immune reactive to neurofilament and weakly immune reactive to podoplanin or epithelial membrane antigen (EMA) with minimal values of hyaluronan. Epithelioid variant of malignant peripheral nerve sheath tumour is immune reactive to INI1(70%) [6,7].

- schwannoma is a benign, peripheral nerve sheath tumour comprised predominantly of Schwann cells. The neoplasm is associated with somatic and germline mutations of NF2 gene. The circumscribed, encapsulated, cellular neoplasm depicts Verocay bodies with alternating foci of hyper-cellular Antoni A and hypo-cellular Antoni B areas. Schwannoma commonly appears within 20 years to 50 years. Although sporadic, the neoplasm may emerge in concurrence with neurofibromatosis type 2 and exceptionally with neurofibromatosis type1. Plexiform variant is infrequent [6,7].

The neoplasm is diffusely and uniformly immune reactive to S100 protein, intensely immune reactive to calretinin with scattered immune reactivity to CD34 and focal or absent immune reactivity to factor XIIIa. Malignant metamorphosis is extremely exceptional [6].

- perineuroma is an exceptional, benign, mesenchymal neoplasm engendered from perineurial cells, which lacks concurrence with neurofibromatosis. The neoplasm is immune reactive to epithelial membrane antigen (EMA), Claudin-1, GLUT1, is variably immune reactive to CD34 and is immune non-reactive to S100 protein.

- dermatofibroma is a benign, neoplastic proliferation composed of fibroblasts and histiocytes. Tumefaction emerges as an indurated, dermal papule. The neoplasm is immune reactive to factor XIIIa (FXIIIa), CD163 or CD68 and is immune non-reactive to CD34 [6,7].

- dermatofibrosarcoma protubersan is a low grade, locally aggressive, fibroblastic sarcoma appearing within the dermis and subcutaneous tissue and is associated with COL1A1-PDGFB genomic fusion. Tumefaction demonstrates proportion of localized tumour reoccurrence at 50% with enhanced possibility of tumour progression and distant metastasis. The neoplasm is diffusely immune reactive to CD34 and immune non-reactive to S100 protein or factor XIIIa [6,7].

- palisaded encapsulated neuroma is a moderately cellular neoplasm. Epithelial membrane antigen (EMA) demonstrates a delicate, peripheral immune reactivity [6,7]

- superficial leiomyoma is a benign, dermal, smooth muscle neoplasm. It may emerge from the arrector pili muscle, thereby designated as pilo-leiomyoma. The neoplasm
is immune reactive to smooth muscle actin (SMA), muscle specific actin (MSA) and desmin [6,7].

- **neurotized melanocytic nevus** is a benign nevus comprised of nests and aggregates of melanocytic cells disseminated within a loosely cohesive, neuron-laden stroma. Neurotized nevus is immune reactive to S100 protein although nevi are immune reactive to melan A and immune non-reactive to factor XIIIa [6,7].

- **ganglioneuroma** is a benign neoplasm of neural crest origin, constituted by ganglion cells which arise from peripheral nerves. Tumefaction is commonly discerned within the posterior mediastinum or retroperitoneum. Neoplastic Schwann cells are immune reactive to S100 protein and ganglion cells are immune reactive to synaptophysin. •plexiform fibrohistiocytic tumour is an infiltrative, mesenchymal neoplasm composed of fibroblasts and histiocytes. The tumour commonly emerging upon the dermal-subcutaneous junction, is immune reactive to smooth muscle actin (SMA) and immune non-reactive to S100 protein [6,7].

- **nerve sheath myxoma** is a hypocellular neoplasm with an abundance of stromal mucopolysaccharides [7].

- **desmoplastic melanoma** is an invasive variant of malignant melanoma simulating a dermal scar and is frequently associated with malignant melanoma-in-situ. Upon discernment, enlarged tumefaction demonstrates cytological atypia with occurrence of peripheral lymphoid aggregates [6,7]. Desmoplastic malignant melanoma is a neoplasm emerging with sun damaged cutaneous surfaces. The neoplasm commonly configures atypical, junctional, melanocytic hyperplasia or can emerge as melanoma-in-situ. Tumour cells denominate elongated, hyperchromatic cells, a distinctive “packeted” pattern of tumour progression, foci of dense fibrosis and deep-seated, nodular lymphoid aggregates. The neoplasm is immune reactive to S100 protein and SOX10 [6,7].

- **Tumefaction** is immune non-reactive for melanocytic markers such as human melanoma black 45 (HMB45) antigen, melan A and tyrosinase. Exceptional, patchy immune reactivity to CD34 is observed.

- **neurothekeoma** is comprised of cellular, myxoid or mixed variants. Spindle-shaped or epithelioid tumour cells with abundant cytoplasm and indistinct cellular outline are admixed within a myxoid matrix with peripheral fibrosis. Nuclear atypia is variable and mitotic figures are frequent with atypical mitosis. The neoplasm is immune reactive to vimentin, NKI/C3, CD10 and microphthalmia transcription factor (MiTF) and is immune non-reactive to S100 protein and melan A [6,7].

### 8. Investigative Assay

Solitary, superficial lesions can be adequately assessed with physical examination and/or obtainment of cogent tissue samples with subsequent microscopic examination. Enlarged lesions require tissue evaluation and/or assessment with computerized tomography (CT) or magnetic resonance imaging (MRI) in order to assess extent of lesion and optimal surgical strategy [8].

Upon computerized tomography (CT), a well-defined, hypodense nodule with minimal or absent enhancement upon contrast administration is exhibited. Upon magnetic resonance imaging (MRI) tumefaction appears hypo-intense with T1 weighted imaging and hyper-intense upon T2 weighted imaging with heterogeneous contrast enhancement [7,8]. Upon MRI, superficial neurofibroma demonstrates homogenous or heterogeneous signal characteristics devoid of target. Adoption of whole body, hybrid positron emission tomography with magnetic resonance imaging (PET/MRI) in individuals with neurofibromatosis type I can be employed for discerning malignant transformation into malignant peripheral nerve sheath tumour. However, radiographic modalities may not suitably distinguish between neurofibroma and schwannoma [7,8].

### 9. Therapeutic Options

Comprehensive surgical excision is a preferred treatment strategy and suitably alleviates the lesion. Localized tumour reoccurrence is extremely exceptional. Additional, alternative treatment options for managing cutaneous neurofibroma are absent. Instances with diffuse or plexiform neurofibroma, devoid of comprehensive surgical extermination, are subjected to total neoplastic resection for cosmetic or symptomatic relief. Adequate monitoring to assess rapid tumour evolution or reoccurrence can be adopted [7,8].

Sporadic lesions or superficial lesions un-associated with neurofibromatosis type I can be subjected to marginal surgical excision. Deep-seated neurofibroma is managed conservatively. Occasionally, transection from parent nerve can be challenging, necessitating forfeiture of parent nerve in order to ensure comprehensive tumour resection [7,8].

Inherited neoplasms occurring in concurrence with neurofibromatosis type I require non-surgical therapy with preliminary discernment and risk stratification. Agent selumetinib is beneficially adopted in children.

Plexiform neurofibroma is challenging to excise and incomplete resection is associated with frequent tumour relapse. Imatinib is employed for treating plexiform neurofibroma. Interferon- alpha is beneficial for progressive, symptomatic plexiform neurofibroma, unamenable to surgical resection [7,8].
Complications occurring with localized neurofibroma are contingent to surgical extermination with appearance of pain, haemorrhage, scarring and localized infection. Complications with plexiform neurofibromas are associated with intrinsic surgical procedures and are rarely due to inadequate eradication of the lesion. Neurofibromatosis 1 and persistent lesions are associated with enhanced possible malignant metamorphosis with emergence of malignant peripheral nerve sheath tumour [7,8].

Neurofibroma is a benign neoplasm with extremely exceptional localized reoccurrence following comprehensive excision. Proportion of malignant metamorphosis is exceedingly minimal although malignant transformation occurs in approximately 10% instances associated with mutated NF1 gene [7,8].

Malignant metamorphosis into malignant peripheral nerve sheath tumour can emerge within deep-seated neurofibroma arising as a component of neurofibromatosis type I. Low grade malignant peripheral nerve sheath tumour is associated with diffuse nuclear atypia, enhanced cellularity and minimal mitotic activity. Nuclear atypia is denominated by nuclear enlargement (nuclear diameter exceeding ≥ 3 times normal nuclei of Schwann cells) and hyperchromatic nuclei [7,8].

Emergence of plexiform neurofibroma is indicative of neurofibromatosis1 (NF1) disorder. Plexiform subtype is commonly associated with and appears as a precursor to malignant nerve sheath tumour. Subjects delineating multiple, localized neurofibromas mandate additional evaluation [7,8].

References
5. Garozzo D. Peripheral nerve tumours in neurofibromatosis1- an overview on management and indications for surgical treatment in our experience. Neurol India. 2019; 67(supplement): S38-S44.